Sunovion Pharmaceuticals announced that Health Canada approved the Supplemental New Drug Submission (SNDS) to expand the indication for its antiepileptic drug (AED) Aptiom (eslicarbazepine acetate) to include use as an adjunctive therapy for the treatment of partial-onset seizures (POS) in adolescents and children above six years of age who are not satisfactorily controlled with conventional therapy.…
Sunovion Receives Health Canada Acceptance of New Drug Submission for Apomorphine Sublingual Film
Sunovion announced that Health Canada has accepted the New Drug Submission (NDS) for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes), experienced by people living with Parkinson’s disease (PD), including those who experience early morning OFF episodes. OFF episodes can cause severe disruption for someone living with PD, often causing a major disturbance in…
